Fusobacterium necrogenes

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Fusobacterium necrogenes is a Gram-negative, non-spore-forming, strictly anaerobic, rod-shaped bacterium. It has been detected in at least 6 gut microbiome compilation studies or metastudies. Fusobacterium necrogenes is probably a rare gut coloniser. (Gharbia2010Bergey)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Gharbia2010Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • 💧
  • Bile tolerance:
  • Grows in the presence of bile
  • ⥅
  • Substrates assimilated or utilised:
  • glucose; mannose;
  • Active enzymes:
  • alkaline phosphatase; acid phosphatase; α-galactosidase; β-galactosidase;
    • SPECIAL FEATURES (Gharbia2010Bergey);
    Character Response
  • ✗
  • Haemolysis:
  • absent
    • RESPONSE TO ANTIBIOTICS (Goldstein2006); (Goldstein1999); (Schaumann1999); (Goldstein1999b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; imipenem; penicillin G;
  • Cephalosporins:
  • cefoxitin;
  • Macrolides:
  • azithromycin; clarithromycin; erythromycin; roxithromycin; telithromycin;
  • Quinolines:
  • gatifloxacin; gemifloxacin; trovafloxacin;
  • Heterocycles:
  • metronidazole;
  • Miscellaneous antibiotics:
  • clindamycin;
  • telithromycin;

  • Finegold, S. M., Howard, R. A., & Vera, L. S. (1974). Effect of diet on human intestinal fecal flora: comparison of Japanese and American diets. Am. J. Clin. Nutr, 27, 1456–1469.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Fusobacteria Class:  Fusobacteriia Order:  Fusobacteriales Family:  Fusobacteriaceae Genus:  Fusobacterium Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    Bile reaction(%):  +
    		Aesculin:  +
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Fructose:  w Glucose:  w(+) Mannose:  w(+) Lactose:  neg Maltose:  neg Raffinose:  neg Sucrose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg AlkalineP:  + AcidP:  + Esterase(C4):  neg EstLip(C8):  neg Lipase:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 1, MIC90: 2, RNG: (0.125->4)
    amp-sulb:  S(MIC50): 0.06, MIC90: 1, RNG: (0.06–1)
    penicillin_G:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.015->32)
    imipenem:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06-4)
    cefotaxime:  Var(MIC50): 0.5, MIC90: >32, RNG: (0.25->32)
    cefoxitin:  S(MIC50): 4, MIC90: 8, RNG: (0.25–8)
    azithromycin:  R(MIC50): 16, MIC90: 32, RNG: (1->32)
    erythromycin:  R(MIC50): >32, MIC90: >32, RNG: (2->32)
    clarithromycin:  R(MIC50): >32, MIC90: >32, RNG: (4->32)
    roxithromycin:  R(MIC50): >32, MIC90: >32, RNG: (8->32)
    telithromycin:  R(MIC50): 32, MIC90: >32, RNG: (2–>32)
    ciprofloxacin:  Var(MIC50): 4, MIC90: 16, RNG: (0.125->32)
    gatifloxacin:  S(MIC50): 1, MIC90: 8, RNG: (0.06-8)
    gemifloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125–16)
    levofloxacin:  Var(MIC50): 8, MIC90: >16, RNG: (1–>16)
    moxifloxacin:  Var(MIC50): 1, MIC90: 4, RNG: (0.125–>16)
    sparfloxacin:  Var(MIC50): 8, MIC90: 16, RNG: (1–>16)
    trovafloxacin:  S(MIC50): 4, MIC90: 4, RNG: (1->8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    metronidazole:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1)
    clindamycin:  S(MIC50): 1, MIC90: 8, RNG: (0.06-8)

    References

    SPECIFIC REFERENCES FOR FUSOBACTERIUM NECROGENES
  • Gharbia2010Bergey - Bergey's manual of systematic bacteriology. Vol. 4, The Fusobacteria. Family Fusobacteriaceae, Genus I. Fusobacterium
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999 - In vitro activity of gemifloxacin (SB 265805) against anaerobes.
  • Schaumann1999 - In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR FUSOBACTERIUM NECROGENES
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Benno1989 - Comparison of fecal microflora of elderly persons in rural and urban areas of Japan.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • Added: April 08, 2021